August 20, 2025Open Access

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Methylation-based ctDNA tumor fraction predicts long-term clinical benefit for patients on immune checkpoint inhibitors, enhancing treatment decisions.
In a real-world study of pan-cancer patients, higher tumor fraction indicated better clinical outcomes from immune therapies.
Analysis focused on a cohort of evaluable patients, utilizing methylation data to assess treatment responses and benefits.
Findings highlight the potential for integrating ctDNA monitoring into routine oncological care, helping tailor therapies for better patient outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Real-world analysis shows tumor fraction relates to clinical benefit in patients receiving immune checkpoint inhibitors, suggesting potential for improved cancer treatment strategies.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94feddd0 https://doi.org/10.1158/2767-9764.29948060

View Full Paper

Ask AI

Bookmark

Implication

Real-world analysis shows tumor fraction relates to clinical benefit in patients receiving immune checkpoint inhibitors, suggesting potential for improved cancer treatment strategies.

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Discussion

Implication

Cite This Study

Table 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Discussion

Implication

Cite This Study

Also Consider

Also Consider